Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The prognosis of DLBCL with MYC rearrangement is dismal. Previous study showed that
lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA
EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators
therefore design this phase I/II study to investigate the safety and efficacy of lenalidomide
in combination with R-DA EPOCH in patients with untreated MYC-rearranged DLBCL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University